Key result
Catheter-directed therapies for acute PE improve surrogate RV outcomes with lower bleeding than systemic thrombolysis.
Why the study?
Current PE risk stratification tools poorly predict short-term deterioration or long-term consequences, and randomized trial data supporting catheter-directed interventions are limited.
Do advanced catheter-directed and systemic reperfusion therapies improve clinical and hemodynamic outcomes without excess bleeding compared to anticoagulation alone in patients with intermediate- and high-risk pulmonary embolism?
Do advanced catheter-directed and systemic reperfusion therapies improve clinical and hemodynamic outcomes without excess bleeding compared to anticoagulation alone in patients with intermediate- and high-risk pulmonary embolism?
This narrative review synthesizes current risk stratification limitations and the evidence for emerging catheter-directed therapies in intermediate- and high-risk pulmonary embolism, highlighting the need for ongoing randomized trials to establish hard clinical benefit over anticoagulation alone.
Answers are grounded in this paper and cite their sources.
Catheter-directed interventions may reduce bleeding versus systemic thrombolysis in intermediate- and high-risk PE; leaves open hard outcome benefits over anticoagulation alone.
Acute pulmonary embolism (PE) is a leading cause of mortality. Not only is PE associated with short-term mortality, but up to ~20% of patients might suffer from long-term consequences such as post-PE syndrome and chronic thromboembolic pulmonary hypertension. Current risk stratification tools poorly predict those who are at risk for short-term deterioration and those who develop long-term consequences. Traditionally, systemic thrombolysis has been considered the first-line therapy for patients with high-risk PE without contraindications; however, it comes with the risk of major bleeding (notably intracranial hemorrhage). The use of catheter-directed interventions (embolectomy or thrombolysis) has been increasing owing to their low bleeding risk; however, randomized trial data supporting their efficacy in improving clinical outcomes are limited. In this review, we highlight the evidence supporting the available advanced therapies for high- and intermediate-risk PE and summarize the ongoing trials which are evaluating these therapies.
No takes yet. Share an insight, caveat, or question.
Mojaddedi et al. (2024) conducted a review in Intermediate- and high-risk acute pulmonary embolism. Advanced reperfusion therapies (systemic thrombolysis, catheter-directed thrombolysis, catheter-directed embolectomy, surgical thrombectomy, VA-ECMO) vs. Systemic anticoagulation alone was evaluated. Catheter-directed interventions for intermediate- and high-risk pulmonary embolism improve surrogate right ventricular outcomes with lower bleeding risk than systemic thrombolysis.
Synapse has enriched 10 related papers. Consider them for comparative context: